Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.42 |
| ▸ | PLD2 | O14939 | 3/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.40 |
| ▸ | TNKS | O95271 | 4/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13489657 | 0.94 | AVPR1A (0.46) | AVPR1ACHRM1PLD2PLD1ALDH1A1 | |
| SCHEMBL438837 | 0.90 | AVPR1A (0.48) | AVPR1ACHRM1PLD2PLD1HSD11B1 | |
| SCHEMBL13490140 | 0.87 | ALDH1A1 (0.41) | AVPR1ACHRM1PLD2PLD1ALDH1A1 | |
| SCHEMBL13996306 | 0.85 | AVPR1A (0.46) | AVPR1ACHRM1PLD2PLD1ALDH1A1 | |
| SCHEMBL1051338 | 0.82 | HSD11B1 (0.49) | AVPR1ACHRM1PLD2PLD1HSD11B1 | |
| SCHEMBL438838 | 0.80 | AVPR1A (0.47) | AVPR1ACHRM1PLD2PLD1HSD11B1 | |
| SCHEMBL13996311 | 0.80 | AVPR1A (0.48) | AVPR1ACHRM1PLD2PLD1HSD11B1 | |
| SCHEMBL14001194 | 0.78 | PLD2 (0.40) | AVPR1ACHRM1PLD2PLD1ALDH1A1 | |
| SCHEMBL4635951 | 0.70 | CHRM1 (0.67) | AVPR1ACHRM1PLD1ALDH1A1HSD11B1 | |
| SCHEMBL3390173 | 0.68 | AVPR1A (0.54) | AVPR1ACHRM1HSD11B1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | CMA1, SERPINB1, TPSAB1 | AVPR1A 3879/4885CHRM1 3056/4885PLD2 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.